GlassScriptPhysician profile
Herbert Charles Smitherman, JR.
NPI 1518905637
$3,763.50
in general payments reported to CMS, 2019-2025
28 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $47.27 · 2021: $179 · 2022: $355 · 2023: $1,212 · 2024: $650 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $507.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $368.23 | 2021-2024 | Ubrelvy, Linzess, Creon |
| Teva Pharmaceuticals USA, INC. | $334.68 | 2019-2023 | Austedo |
| Abbott Laboratories | $334.63 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $303.26 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $252.44 | 2019-2025 | Mounjaro, Jardiance |
| Amarin Pharma, INC. | $156.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.06 | 2023 | |
| Novartis Pharmaceuticals Corporation | $130.95 | 2019 | |
| Boston Scientific Corporation | $130.85 | 2023 | Watchman Access System |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Modernatx, INC. | $120.67 | 2023 | Moderna Covid-19 Vaccine |
| Abiomed | $113.25 | 2025 | |
| Sanofi Pasteur INC. | $111.16 | 2023 | |
| Alnylam Pharmaceuticals INC. | $110.88 | 2023 | Amvuttra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.18 | 2019-2024 | Repatha |
| Exact Sciences Corporation | $96.38 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $51.46 | 2021-2022 | |
| Novo Nordisk INC | $47.77 | 2021-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $46.59 | 2025 | Veozah |
| Dexcom, INC. | $39.67 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $30.51 | 2021 | |
| Nestle Healthcare Nutrition INC. | $24.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.09 | 2024 | Jardiance |
| Biogen, INC. | $23.51 | 2022 | |
| Intuitive Surgical, INC. | $14.77 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.42 | 2025 | Zoryve |
| Vivaquant INC, Dba Rhythm Express | $13.40 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Smitherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.